(ii) The early cognitive decline based on predominant α-synuclein-driven pathology offers the opportunity to address PD-associated dementia with disease-modifying agents in a clearly defined prodromal phase preceding dementia and based on clear biological stratification. Here, SNCA is linked to Mental deterioration.